We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.70 | 1.85% | 93.58 | 93.57 | 93.58 | 93.74 | 92.26 | 92.30 | 386,781 | 14:35:55 |
From May 2019 to May 2024
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Sanofi SA on Tuesday said a pivotal phase 3 study of the eczema drug Dupixent met its primary and all key secondary endpoints in children ages six to 11 years old with uncontrolled moderate-to-severe asthma.
The companies said Dupixent added to standard of care significantly reduced severe asthma attacks by up to 65% over one year compared to a placebo, adding that significant and rapid improvement in lung function was seen within two weeks and sustained for up to 52 weeks.
Regeneron and Sanofi said they plan to file for U.S. and European regulatory approval in the indication by the first quarter of next year.
Regeneron, of Tarrytown, N.Y., created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement. Sanofi markets the product internationally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 13, 2020 06:22 ET (10:22 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
